AstraZeneca and G42 Healthcare signed a strategic cooperation agreement aimed at manufacturing innovative pharmaceutical products for AstraZeneca in Abu Dhabi.
The partnership focuses on four main axes: the localization of innovative industries, scientific research, development, innovation and sustainability at the global level, which enhances the position of the capital, Abu Dhabi, as an incubator for innovation and research in the life sciences.
The signing of the agreement was attended by His Excellency Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health – Abu Dhabi, Pascal Soriot, CEO of “AstraZeneca” company, His Excellency Dr. Jamal Muhammad Al Kaabi, Undersecretary of the Department of Health – Abu Dhabi, and Peng Chao, CEO of the “G42” group.
The cooperation agreement was signed by Ashish Koshy, CEO of G42 Healthcare, and Belen Enciso, Vice President for the Middle East and Africa, and AstraZeneca. The signing was also witnessed by a number of representatives of government agencies, including the Ministry of Health and Community Protection, the Ministry of Industry and Advanced Technology, and the Abu Dhabi Investment Office.
The agreement strengthens efforts to establish a competitive national economy based on knowledge, with the aim of making a quantum leap in the healthcare system in Abu Dhabi, by unleashing national potential, as “AstraZeneca” and “G42 Healthcare” have defined a long-term plan to manufacture innovative medicines in Abu Dhabi based on On the distinguished infrastructure of the health sector in the emirate.
The partnership contributes to the efforts made within the “Abu Dhabi Industrial Strategy” aimed at doubling the size of the manufacturing sector in the emirate by 2031. The agreement will also expand the scope of research and development in life sciences in Abu Dhabi, in addition to enabling innovation in the areas of health care, where all parties will cooperate concerned to present the latest scientific innovations and practices that enhance the provision of medicines to patients in the UAE and enhance its export competitiveness.
The Department of Health – Abu Dhabi seeks to provide a vital and effective role in the knowledge-based economy in the UAE by creating unique job opportunities that require experienced and knowledgeable human competencies, in line with the vision of “We Are the Emirates 2031”, especially in terms of raising the gross domestic product and increasing the country’s non-oil exports. The agreement is expected to attract the best talent in the health field and position the UAE among the top 10 countries in the field of healthcare.
His Excellency Dr. Jamal Mohammed Al Kaabi, Undersecretary of the Department of Health – Abu Dhabi, said, “Under the directives of our wise leadership, the UAE continues to consolidate its leading position in providing research and innovation as part of the continuous efforts to strengthen the healthcare sector. We are working in the Department of Health – Abu Dhabi, in cooperation with our global partners, to continue exploring and consolidating ways of cooperation.” It enhances the sustainability and resilience of health care systems around the world while ensuring the provision of high quality healthcare to patients.
He added, “While we continue to consolidate the emirate’s position as a leading destination for healthcare and an incubator for innovation in life sciences, we are pleased to support local pharmaceutical manufacturing efforts in Abu Dhabi, which is a true reflection of the goals of the ‘Make in the UAE’ campaign and the global interest in investing in the vital pharmaceutical and healthcare sectors in Abu Dhabi as a fruit of potential.” developmental and distinguished infrastructure enjoyed by the emirate.
“AstraZeneca is honored to be a strategic partner of the UAE in providing innovative healthcare at the local level,” said Sameh Al-Fangary, Head of the GCC and Pakistan Region at AstraZeneca.
It is worth noting that in 2021, Abu Dhabi doubled its capabilities to develop scientific and clinical research, as it conducted more research projects within one year than the research projects it conducted during the previous five years.
The Department of Health – Abu Dhabi has launched the “Covid-19 Research Registry” to serve as a unified platform to support global research efforts to confront the pandemic. The department received more than 376 research papers in 2021, and 67 health facilities in Abu Dhabi were licensed for scientific research. Today, there are more than 400 clinical research trials underway in the emirate.
For his part, Ashish Koshy, CEO of G42 Healthcare, said, “We are confident of the potential of our continued partnership with AstraZeneca and its returns to the healthcare sector in the UAE, which is intensifying its efforts to become a global center for innovation and research in the life sciences. The strategic collaboration will accelerate the pace of innovation in local manufacturing and will allow us to explore greater possibilities in clinical research to deliver therapies that improve the lives of patients in the UAE and across the region.”
He added, “We consider one of the most important goals of this partnership to enhance sustainable manufacturing capabilities and drive innovation at the global level, as we all envision better healthcare for all.”
Abu Dhabi is preparing to develop one of the largest drug storage facilities, as part of its constant endeavor to enhance health care at all levels, and it is scheduled to start operating soon. .
#G42 #AstraZeneca #sign #agreement #manufacture #innovative #pharmaceutical #products